CriticalAntidepressants. Other antidepressants of herbal origin×Calcineurin inhibitor (immunosuppressant)
Updated · Methodology
Mechanism
CYP3A4 and CYP3A5 metabolise tacrolimus, mainly in the liver, and a considerable part of its metabolism also takes place in the intestinal wall (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). Hyperforin in St John's wort induces CYP3A4, CYP2B6, CYP2C9, CYP2C19 and the transporter P-glycoprotein in a dose-dependent way (St John's wort herbal monograph, European Medicines Agency, EMA, sections 4.5 and 5.2). The tacrolimus documents class St John's wort as a strong CYP3A4 inducer that may lower tacrolimus trough blood levels and increase the risk of rejection (tacrolimus SmPC, AEMPS, section 4.5; tacrolimus label, US Food and Drug Administration, FDA, section 7.2). According to the Spanish tacrolimus SmPC, the largest fall in tacrolimus levels may come after 1–2 weeks of combined use. The effect may last another 1–2 weeks after the inducer is stopped (tacrolimus SmPC, AEMPS, section 4.5). The St John's wort monograph, however, says that increased enzyme activity returns to normal within 1 week (St John's wort herbal monograph, EMA, section 4.5). After the inducer is stopped, tacrolimus levels may, conversely, rise above the therapeutic range (tacrolimus SmPC, AEMPS, section 4.4).
Symptoms
Tacrolimus blood levels fall and the risk of transplant rejection rises (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5; tacrolimus label, US Food and Drug Administration, FDA, section 7.2). The Spanish St John's wort SmPC also lists lower tacrolimus levels with a risk of rejection (St John's wort SmPC, AEMPS, section 4.5). Tacrolimus is used to prevent rejection after liver, kidney or heart transplantation and to treat rejection that does not respond to other immunosuppressants (tacrolimus SmPC, AEMPS, section 4.1). The fall shows in tacrolimus blood level tests. After St John's wort is stopped, levels may rise above the therapeutic range. This raises the risk of serious tacrolimus adverse reactions, including kidney and nervous system toxicity and QT prolongation (tacrolimus SmPC, AEMPS, section 4.4).
Management
The combination is contraindicated. The European Medicines Agency (EMA) herbal monograph contraindicates St John's wort with systemic tacrolimus. For well-established use products it applies without conditions, and for traditional use products it applies when the daily hyperforin dose exceeds 1 mg (St John's wort herbal monograph, EMA, sections 4.3 and 4.5). The Spanish St John's wort summary of product characteristics (SmPC) names tacrolimus explicitly among its contraindications (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of that product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The tacrolimus documents are less strict. They advise avoiding St John's wort products during tacrolimus treatment and giving CYP3A4 inducers with tacrolimus only after consulting a transplant specialist (tacrolimus SmPC, AEMPS, sections 4.4 and 4.5). If the combination cannot be avoided, the tacrolimus dose may need to go up. Adjust it to tacrolimus trough blood levels: measure them at the start, monitor them frequently from the first days and reassess them after the inducer course ends. Monitor graft function closely (tacrolimus SmPC, AEMPS, section 4.5). The US label lists St John's wort among strong inducers and says to increase the tacrolimus dose and monitor trough levels (tacrolimus label, US Food and Drug Administration, FDA, section 7.2). After St John's wort is stopped, tacrolimus levels may rise above the therapeutic range. Monitor them closely under the supervision of a transplant specialist and adjust the dose gradually if needed (tacrolimus SmPC, AEMPS, sections 4.4 and 4.5). The contraindication concerns systemic tacrolimus. According to the Spanish St John's wort SmPC, St John's wort products probably do not interact with topical medicines that have limited systemic absorption, such as creams and ointments (St John's wort SmPC, AEMPS, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Prograf 0,5 mg cápsulas duras (tacrolimus) (2026)– AEMPS, CIMA, nº registro 63189, secciones 4.4 y 4.5
- FDA: Prograf (tacrolimus) prescribing information (2025)– Astellas Pharma US. PROGRAF (tacrolimus) capsules, injection, granules. Prescribing information, DailyMed setid 7f667de1-9dfa-4bd6-8ba0-15ee2d78873b, sections 4, 5.11 and 7
- EMA: Ficha técnica: Tacrolimus, Advagraf (EU/1/07/387), sección 4.5 (2026)– EMA SmPC vía AEMPS CIMA, nº registro 07387017 (EU/1/07/387), sección 4.5, texto vigente consultado 10/2026
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5